{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:58:28Z","timestamp":1787407108832,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Emicizumab significantly reduces bleedings in patients with hemophilia A (PwHA). A clinical study (HAVEN 7; NCT04431726) for PwHA aged less than or equal to 12\u00a0months is ongoing, but emicizumab\u2010driven coagulation potential in PwHA in early childhood remains to be clarified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the in vitro or in vivo coagulation potential of emicizumab in plasmas obtained from infant and toddler PwHA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010seven plasma samples from 14 infant\/toddler PwHA (aged 0\u201342\u00a0months, median 19\u00a0months) who received emicizumab (<jats:italic>n<\/jats:italic>\u00a0=\u00a09), factor (F)VIII products (<jats:italic>n<\/jats:italic>\u00a0=\u00a08), or no treatment (<jats:italic>n<\/jats:italic>\u00a0=\u00a010) were obtained. FVIII activity in FVIII\u2010treated plasmas was cancelled by the addition of anti\u2010FVIII monoclonal antibody (mAb). Emicizumab\u2010treated plasmas (in vivo) and emicizumab\u2010spiked plasmas (in vitro) were analyzed. Emicizumab\u2010untreated plasma or emicizumab\u2010treated plasma supplemented with two anti\u2010emicizumab mAbs were used as references. Adjusted maximum coagulation velocity (Ad|min1|) by clot waveform analysis and peak thrombin (Peak\u2010Th) by thrombin generation assay was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ad|min1| values in 24 samples were improved by the presence of emicizumab. Values did not improve in the three remaining samples (aged 1, 23, and 31\u00a0months). Although the presence of emicizumab showed an age\u2010dependent increase in Peak\u2010Th in 20 samples, this increase was not observed in seven samples (aged 0, 1, 1, 2, 8, 19, and 36\u00a0months). Emicizumab\u2010dependent increases in both Ad|min1| and Peak\u2010Th were shown in 18 samples, and increases in either parameter were shown in eight samples. One sample (from patient aged 1\u00a0month) showed no increase in both, however.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Emicizumab could improve coagulant potential in plasmas from infant\/toddler patients with hemophilia A.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.30590","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T16:40:04Z","timestamp":1689784804000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A"],"prefix":"10.1002","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-9815","authenticated-orcid":false,"given":"Masahiro","family":"Takeyama","sequence":"first","affiliation":[{"name":"Department of Pediatrics Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Abe","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Harada","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-6915","authenticated-orcid":false,"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University Kashihara Nara Japan"},{"name":"The Course of Thrombosis and Hemostasis Molecular Pathology Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University Kashihara Nara Japan"},{"name":"Advanced Medical Science of Thrombosis and Hemostasis Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University Kashihara Nara Japan"},{"name":"Division of Hemophilia National Hospital Organization Osaka National Hospital Osaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Soeda","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-200407000-00004"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13461"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006684"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13618"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14363"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00377-5"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12837"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13848"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27886"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29731"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14022"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00507a028"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-585737"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14662"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13266"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16964"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"key":"e_1_2_11_28_1","first-page":"378","article-title":"Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years","volume":"17","author":"Zanon E","year":"2019","journal-title":"Blood Transfus"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15342"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.30590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T13:38:46Z","timestamp":1692797926000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.30590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/pbc.30590"],"URL":"https:\/\/doi.org\/10.1002\/pbc.30590","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"2023-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e30590"}}